Literature DB >> 1980465

Biliary excretion of H2-receptor antagonists.

U Klotz1, S Walker.   

Abstract

The biliary excretion of ranitidine and famotidine has been studied using percutaneous biliary drainage in patients with complete extrahepatic biliary obstruction due to pancreatic carcinoma. Following 50 mg ranitidine i.v. 0.7 to 2.6% of the dose was recovered in bile collected over 24 h. At steady state (300 mg ranitidine/d po) a similar amount (0.3 to 1.0% of daily dose) was excreted by this route (n = 3). Following single i.v. (20 mg) and oral (40 mg) doses of famotidine (n = 2), even lower percentages (0.1% and 0.4%, respectively) were recovered in the 24 h bile. This negligible biliary excretion cannot account for the so-called second peak phenomenon observed in some individuals following a single dose of an H2-receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980465     DOI: 10.1007/bf02657067

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

Review 1.  Newer H2-receptor antagonists. Clinical pharmacokinetics and drug interaction potential.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

2.  Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.

Authors:  A M van Hecken; T B Tjandramaga; A Mullie; R Verbesselt; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

5.  Pharmacokinetics of famotidine in man.

Authors:  H Kroemer; U Klotz
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-08
  5 in total
  5 in total

1.  A modified two-portion absorption model to describe double-peak absorption profiles of ranitidine.

Authors:  Ophelia Q P Yin; Brian Tomlinson; Albert H L Chow; Moses S S Chow
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Effect of pancreatico-biliary secretions and GI transit time on the absorption and pharmacokinetic profile of ranitidine in humans.

Authors:  K S Reynolds; M H Song; W D Heizer; C B Burns; D A Sica; K L Brouwer
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

3.  Regional gastrointestinal absorption of ranitidine in the rat.

Authors:  A B Suttle; K L Brouwer
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

4.  A modern view of excipient effects on bioequivalence: case study of sorbitol.

Authors:  M-L Chen; A B Straughn; N Sadrieh; M Meyer; P J Faustino; A B Ciavarella; B Meibohm; C R Yates; A S Hussain
Journal:  Pharm Res       Date:  2006-10-18       Impact factor: 4.580

5.  Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.

Authors:  Marleen Julia Meyer; Tina Seitz; Jürgen Brockmöller; Mladen Vassilev Tzvetkov
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.